MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

2.620 +0.320 (+13.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Ovid Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Looking Into Ovid Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
3 Very Promising Penny Stocks That Are Flying Under the Radar ↗
Although the very concept of penny stocks to buy screams risk, these ideas just might be intriguing enough for speculators. 
Via InvestorPlace
News headline image
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Added to Russell 3000® Index
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023 ↗
 
Via Benzinga
News headline image
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech ↗
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
News headline image
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
News headline image
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
News headline image
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension ↗
 
Via Benzinga
News headline image
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
On Monday, 149 companies reached new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story